Adult Spinal Cord Radial Glia Display a Unique Progenitor Phenotype

Radial glia (RG) are primarily embryonic neuroglial progenitors that express Brain Lipid Binding Protein (Blbp a.k.a. Fabp7) and Glial Fibrillary Acidic Protein (Gfap). We used these transcripts to demarcate the distribution of spinal cord radial glia (SCRG) and screen for SCRG gene expression in the Allen Spinal Cord Atlas (ASCA). We reveal that neonatal and adult SCRG are anchored in a non-ventricular niche at the spinal cord (SC) pial boundary, and express a “signature” subset of 122 genes, many of which are shared with “classic” neural stem cells (NSCs) of the subventricular zone (SVZ) and SC central canal (CC). A core expressed gene set shared between SCRG and progenitors of the SVZ and CC is particularly enriched in genes associated with human disease. Visualizing SCRG in a Fabp7-EGFP reporter mouse reveals an extensive population of SCRG that extend processes around the SC boundary and inwardly (through) the SC white matter (WM), whose abundance increases in a gradient from cervical to lumbar SC. Confocal analysis of multiple NSC-enriched proteins reveals that postnatal SCRG are a discrete and heterogeneous potential progenitor population that become activated by multiple SC lesions, and that CC progenitors are also more heterogeneous than previously appreciated. Gene ontology analysis highlights potentially unique regulatory pathways that may be further manipulated in SCRG to enhance repair in the context of injury and SC disease

A scoping review of clinical pharmacist and pharmacy technician contributions to cystic fibrosis care

The purpose of this scoping literature review was to assess available published literature/abstracts, and to examine described contributions by pharmacists and/or pharmacy technicians as part of the care of people with cystic fibrosis (pwCF). This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Published abstracts and articles from inception through December 2022 were included if they described care of pwCF (all ages), with at least one group of participants receiving care/services from pharmacy staff, and were available in English. Data extractions were outcomes, study, and participant characteristics. From 756 abstracts and papers, 91 were included. The majority were published abstracts (n = 67), from the United States (n = 64), retrospective cohort study design (n = 47), involved pharmacist intervention (n = 75), with no comparison group (n = 48), and in an outpatient/ambulatory setting (n = 59). Most often, literature were descriptions of specific pharmacist services, evaluations of adding a pharmacist, or descriptions of overall pharmacist practice/role. Specific pharmacist services were defined as patient or caregiver education, adherence support, medication reconciliation, management of pulmonary exacerbations, and medication management (including monitoring, and telehealth). Pharmacists and pharmacy technicians have contributed to the care of pwCF in various ways; however, much of the available data are currently disseminated in the form of conference abstracts. Efforts to support author publication of data as full peer-reviewed publications should be prioritized as this data can help support others’ efforts to develop or support similar clinical pharmacy services.Open access articleThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]